SHH and neoplasm: One possible explanation leveraged to explain these contrasting roles is that the duration of Shh inhibition might be the deciding factor on PDAC outcomes, as acute or early inhibition might promote tumor growth, as seen in deletion of Shh in genetic models, while targeting Shh in well-established tumors can decrease the tumorigenic potential and enhance drug delivery.